Endoscopic sclerotherapy using absolute XXXX .

@entity1 @entity82 @entity99 @entity101 @entity548 @entity167 @entity1282 @entity158 @entity204 @entity221
To assess the efficacy of absolute @entity167 as a sclerosant, endoscopic sclerotherapy was carried out using a conventional endoscope and an indigenously designed injector. Forty three @entity1 with portal @entity101 who had presented with history of variceal @entity548 were included in the study. Portal @entity101 was caused by @entity82 in 30 (69.8%), @entity82 in eight (18.6%) and extra-hepatic obstruction in five (11.8%). Acute @entity548 was successfully controlled in all 11 @entity1 , seven with a fresh bleed and four who rebled while on endoscopic sclerotherapy regimen. All @entity1 with fresh, recent, or old @entity548 were treated with a weekly endoscopic sclerotherapy schedule. Reduction in variceal size of two or more grades was achieved in all 20 @entity1 who had completed at least four endoscopic sclerotherapy courses with total eradication of varices in 16 (80%). The mean (+/- SD) number of endoscopic sclerotherapy courses and time required for variceal eradication was 6.06 (+/- 1.87) and 9.1 (+/- 4.69) weeks respectively. None of these @entity1 has shown appearance of fresh varices in a follow up of 18.47 +/- 8.50 weeks (range six to 38 weeks). Six @entity1 died; all @entity204 were caused by progressive @entity99 . Complications usually seen were @entity1282 , @entity158 and @entity221 ; these were mild and easily tolerated by the @entity1 . Rebleeding occurred in four @entity1 who had received less than four endoscopic sclerotherapy courses. Absolute @entity167 appears to be an effective, safe, economical, and freely available sclerosant. advocate endoscopic sclerotherapy as the first line of treatment for @entity548 and recommend a weekly schedule for the early eradication of varices.
